NEWTON, Mass.--(BUSINESS WIRE)--Dec. 9, 2005--Matritech (Amex: MZT), a leading developer of protein-based diagnostic products for the early detection of cancer, presented an improved method of detecting the NMP66(TM) nuclear matrix protein complex in serum from women with breast cancer. The study data were presented in a poster session during the 2005 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
